Novartis (English Wikipedia)

BBC (22 April 2014). "Novartis and GSK exchange assets". BBC. Archived from the original on 29 April 2014. Retrieved 22 April 2014.
Jeffreys, Branwen (6 May 2012). "Using Avastin for eye condition wet AMD 'could save NHS £84m'". bbc.com. Archived from the original on 6 November 2013. Retrieved 6 May 2012.

beuc.eu

"Avastin vs Lucentis" (PDF). Archived (PDF) from the original on 6 August 2020. Retrieved 29 January 2021.

bio.org

"BIO Member Directory | BIO". www.bio.org. Archived from the original on 30 September 2022. Retrieved 1 March 2024.

bioprocessintl.com

Ojha, Shreeyashi (15 November 2023). "Legend & Novartis sign $100m agreement - BioProcess Insider". BioProcess International. Retrieved 30 November 2023.^{[permanent dead link‍]}

biosimilarnews.com

Staff, Biosimilars News. 15 August 2011 Biosimilars approved in Europe Archived 20 October 2013 at the Wayback Machine

biospace.com

Terry, Mark (19 December 2016). "Novartis AG Snaps Up Mid-Stage Eczema Rival". BioSpace. Archived from the original on 6 August 2020. Retrieved 29 October 2018.
"China's Laekna Inks Two-Drug Deal with Novartis | BioSpace". BioSpace. Archived from the original on 5 August 2020. Retrieved 3 August 2018.
"Out From Under Novartis, Alcon Is Its Own Company Now". BioSpace. 9 April 2019. Archived from the original on 23 September 2020. Retrieved 10 April 2019.
"Sandoz Boosts Toehold in Japan with Aspen Acquisition". BioSpace. 11 November 2019. Archived from the original on 6 August 2020. Retrieved 4 May 2020.
Terry, Mark (25 November 2019). "Novartis Buys The Medicines Company: A $9.7 Billion Gamble on a PCSK9 Cholesterol Drug". BioSpace. Urbandale, Iowa. Archived from the original on 6 August 2020. Retrieved 1 December 2019.
"Amblyotech, A Digital Therapeutics Company, Announces It Has Been Acquired by Novartis". BioSpace. Archived from the original on 6 August 2020. Retrieved 4 May 2020.
"Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company". BioSpace. Archived from the original on 7 November 2020. Retrieved 29 January 2021.
"Novartis Expands Footprint in Gene and Cell Therapy with Vedere Bio Acquisition". BioSpace. 29 October 2020. Archived from the original on 25 November 2020. Retrieved 29 January 2021.
"Cadent Therapeutics Enters Agreement to be Acquired by Novartis". BioSpace. Archived from the original on 5 February 2021. Retrieved 29 January 2021.
"Novartis Adds to Optogenetics Portfolio with Arctos Medical Buy". 21 September 2021. Archived from the original on 23 September 2021. Retrieved 23 September 2021.
"Alcon to Officially Spin out From Novartis on April 9". BioSpace. 22 March 2019. Archived from the original on 6 August 2020. Retrieved 9 January 2020.
"Novartis AG to Hold On to Its 33% Stake in Roche—For Now". BioSpace. 12 October 2017. Archived from the original on 1 November 2020. Retrieved 10 January 2020.

bloomberg.com

Kresge, Naomi (25 August 2022). "Novartis to Spin Off Sandoz Generic Drug Unit by Next Year". Bloomberg News. Archived from the original on 25 August 2022.
Pfanner, Eric; Kresge, Naomi (30 June 2023). "Novartis Sells Eye Drugs to Bausch + Lomb for Up to $2.5 Billion". Bloomberg.com. Retrieved 20 June 2023.

boston.com

Ross, Casey (27 October 2010). "Novartis doubles plan for Cambridge". The Boston Globe. Archived from the original on 3 November 2012. Retrieved 31 October 2010.

britannica.com

"Novartis AG | Swiss company". Encyclopedia Britannica. Archived from the original on 27 October 2020. Retrieved 21 January 2020.
"Ciba-Geigy AG | Swiss pharmaceutical company". Encyclopedia Britannica. Archived from the original on 10 October 2017. Retrieved 21 January 2020.

brusselstimes.com

"Pharmaceutical giants fined record €444 million for 'abusive practices'". The Brussels Times. 9 September 2020. Archived from the original on 9 October 2020. Retrieved 13 September 2020.

capital.gr

"Ν. Ηλιόπουλος: Και με τη βούλα της Δικαιοσύνης υπαρκτό το σκάνδαλο Novartis". capital.gr. Archived from the original on 27 July 2022. Retrieved 27 July 2022.

cnbctv18.com

"JB Chemicals acquires around 15 opthalmology drugs from Novartis for ₹1,089 crore". CNBCTV18. 19 December 2023. Archived from the original on 19 December 2023. Retrieved 19 December 2023.

contractpharma.com

"Top 25 Pharma & BioPharma in 2022 | Contract Pharma". www.contractpharma.com. Archived from the original on 6 February 2023. Retrieved 6 February 2023.

doi.org

Macilwain, Colin (1 November 1998). "Berkeley teams up with Novartis in $50m plant genomics deal". Nature. 396 (6706): 5. Bibcode:1998Natur.396....5M. doi:10.1038/23772. ISSN 1476-4687. PMID 9817194.
Dalton, Rex (1 May 1999). "Berkeley dispute festers over biotech deal". Nature. 399 (6731): 5. Bibcode:1999Natur.399....5D. doi:10.1038/19807. ISSN 1476-4687. PMID 10331373.
Dalton, Rex (1 November 2003). "Syngenta ends plant-research deal with Berkeley". Nature. 426 (6964): 216. Bibcode:2003Natur.426..216D. doi:10.1038/426216a. ISSN 1476-4687. PMID 14628007.
Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.

drugs.com

Teva Press Release 12 December 2007 Teva Announces Approval of Generic Trileptal Tablets Archived 20 October 2013 at the Wayback Machine

drugstorenews.com

Johnson, Michael (18 January 2014). "Novartis acquires CoStim Pharmaceuticals". Drug Store News. Lebhar-Friedman. Archived from the original on 25 February 2014. Retrieved 19 February 2014.

dw.com

(http://www.dw.com), Deutsche Welle. "Novartis under investigation for bribery in Greece | Europe| News and current affairs from around the continent | DW | 22.01.2017". DW.COM. Archived from the original on 12 November 2020. Retrieved 7 February 2018.

efpia.eu

"The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original (PDF) on 16 September 2008. Retrieved 25 August 2008.

endpts.com

"Novartis vet is getting another shot at mTOR following the implosion of a longevity pioneer". Endpoints. 16 February 2022. Archived from the original on 14 March 2022. Retrieved 14 March 2022.

espacenet.com

worldwide.espacenet.com

"Espacenet - results view". worldwide.espacenet.com. Archived from the original on 17 November 2018. Retrieved 29 January 2021.

europa.eu

ema.europa.eu

"EU/3/09/671 | European Medicines Agency". Archived from the original on 4 February 2014. Retrieved 29 January 2021.
Staff, European Medicines Agency, 2004. EMEA Scientific Discussion of Glivec Archived 20 September 2018 at the Wayback Machine

imi.europa.eu

Innovative Medicines Initiative, ed. (2008), "IMI-GB-018v2-24042008-CallTopics.pdf", IMI 1st Call 2008: Information Package (ZIP archive), European Commission, archived from the original (PDF) on 24 September 2015, retrieved 16 January 2012

evb.ch

Erklärung von Bern. 8 May 2007 Short questions and answers about the court case initiated by Novartis in India Archived 21 October 2013 at the Wayback Machine

fda.gov

Commissioner, Office of the (11 September 2019). "FDA approves new oral drug to treat multiple sclerosis". FDA. Archived from the original on 9 February 2021. Retrieved 16 October 2019.
"Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules CII". Warning Letters. US Food and Drug Administration. 25 September 2008. Archived from the original on 10 February 2012. Retrieved 2009-08-05.

fiercebiotech.com

"Novartis licenses out unwanted GlaxoSmithKline cancer drugs to Chinese biotech | FierceBiotech". www.fiercebiotech.com. August 2018. Archived from the original on 5 August 2020. Retrieved 3 August 2018.
"Novartis hopes for better luck with bispecifics via $150M upfront Dren Bio deal". Fiercebiotech. Archived from the original on 27 July 2024. Retrieved 25 July 2024.

fiercepharma.com

"Can Novartis' CEO resist going for a megamerger with cash from asset sales? - FiercePharma". www.fiercepharma.com. 30 May 2017. Archived from the original on 30 October 2020. Retrieved 6 February 2018.
Staton, Tracy (21 January 2014). "Novartis to cut 500 Swiss pharma jobs, then staff up in OTC, generics". FiercePharma. Questex. Archived from the original on 26 March 2014. Retrieved 19 February 2014.
Helfand, Cindy (21 August 2015). "Novartis shells out up to $1B to test GSK's Arzerra in MS". FiercePharma. Questex. Archived from the original on 4 April 2016. Retrieved 25 January 2020.
"JPM23: Novartis takes sweeping approach to 'US-first' mindset, exec says". Archived from the original on 12 June 2023. Retrieved 12 June 2023.
"Novartis slashing thousands more jobs in global reorganization, shifting many to India". FiercePharma. 2 February 2014. Archived from the original on 2 August 2019. Retrieved 4 February 2015.
Staton, Tracy (22 April 2014). "Novartis, GSK team up in consumer JV to save big money, gain big scale". FiercePharma. Questex Media Group. Archived from the original on 26 October 2020. Retrieved 16 May 2016.
"Greek officials ban Novartis manager from leaving the country amid widening bribery probe: report | FiercePharma". www.fiercepharma.com. Archived from the original on 9 November 2020. Retrieved 7 February 2018.

firstpost.com

"How the Indian judgment will reverberate across the world". Archived from the original on 18 January 2014.

flashback.se

"Albert Hofmann: LSD - My Problem Child: Use of LSD in Psychiatry". Flashback.se. Archived from the original on 7 July 2006. Retrieved 16 January 2012.

ft.com

Neville, Sarah; Waters, Richard (October 2019). "Novartis and Microsoft join forces to develop drugs using AI". Financial Times. Archived from the original on 4 October 2020. Retrieved 5 November 2019.
"BuyNTech buys Novartis site to boost EU vaccine production". Financial Times. 17 September 2020. Archived from the original on 15 January 2021. Retrieved 21 September 2020.
Mancini, Donato Paolo; Telling, Oliver (25 August 2022). "Novartis to spin off generic drugs unit Sandoz". Financial Times. Archived from the original on 10 December 2022.
Kuchler, Hannah (18 August 2023). "Novartis plans to spin off Sandoz in October". Financial Times. Archived from the original on 4 October 2023. Retrieved 19 September 2023.
"Novartis admits $1.2m in payments to Trump lawyer". Financial Times. Archived from the original on 9 November 2020. Retrieved 10 May 2018.

gabionline.net

Staff, Generics and Biosimilars Initiative, 9 November 2012 Sandoz starts phase III US trial for biosimilar epoetin alfa Archived 20 October 2013 at the Wayback Machine

genengnews.com

"Novartis Buys Ex-U.S. Rights to Ophthotech's Fovista for Up to $1B". News | Industry Watch. Genetic Engineering & Biotechnology News (Paper). Vol. 34, no. 12. Mary Ann Liebert. 15 June 2014. p. 8. Archived from the original on 5 August 2020. Retrieved 25 January 2020.
"Ophthotech Pockets $50M Milestone from Novartis for AMD Treatment". GEN News Highlights. Genetic Engineering & Biotechnology News. Mary Ann Liebert. 8 September 2014. Archived from the original on 11 May 2018. Retrieved 14 September 2014.
"Novartis Takes Stake in Gamida with Option to Fully Buy". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 19 August 2014. Archived from the original on 11 May 2018. Retrieved 25 January 2020.
"Novartis Selling Flu Vaccine Business to CSL for $275M". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 27 October 2014. Archived from the original on 3 September 2018. Retrieved 25 January 2020.
"Array BioPharma Completes Deal with Novartis for 2 Cancer Compounds". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 2 March 2015. Archived from the original on 2 July 2017. Retrieved 25 January 2020.
"Novartis Sells RNAi R&D Portfolio to Arrowhead in $35M Agreement". GEN News Highlights. Genetic Engineering & Biotechnology News. Mary Ann Liebert. 5 March 2015. Archived from the original on 9 April 2015. Retrieved 8 June 2016. Note: appears on page 10 of 1 April 2015 print issue.
"Novartis Acquires Spinifex for $200M+". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 29 June 2015. Archived from the original on 4 March 2016. Retrieved 25 January 2020.
"Novartis Acquires All Remaining Rights to GSK's Ofatumumab". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 21 August 2015. Archived from the original on 23 August 2015.
"Novartis Buys Admune; Licenses Palobiofarma, XOMA Compounds". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 21 October 2015. Archived from the original on 17 August 2017. Retrieved 25 January 2020.
"Novartis Acquires Selexys Pharmaceuticals - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN". 21 November 2016. Archived from the original on 30 October 2018. Retrieved 21 November 2016.
"Novartis Buys Encore Vision for Presbyopia Therapy Eyedrops - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN". 20 December 2016. Archived from the original on 21 December 2016. Retrieved 21 December 2016.
"Top 10 Pharma Companies of 2019". 18 November 2019. Archived from the original on 11 November 2020. Retrieved 29 January 2021.
"Novartis Snags Remaining 23% Stake in Alcon with $12.9B Cash and Share Deal | GEN - Genetic Engineering and Biotechnology News". GEN - Genetic Engineering and Biotechnology News. 15 December 2010. Archived from the original on 13 August 2020. Retrieved 14 January 2020.

ghostarchive.org

Mancini, Donato Paolo; Telling, Oliver (25 August 2022). "Novartis to spin off generic drugs unit Sandoz". Financial Times. Archived from the original on 10 December 2022.

globallegalchronicle.com

Global Legal Chronicle Archived 11 November 2020 at the Wayback Machine Molecular Partners Option and License Agreement with Novartis (30 October 2020)

globenewswire.com

Press Release, Novartis. 21 January 2003 Novartis to Unite Its Generics Businesses Under One Single Global Brand: Sandoz Archived 17 October 2013 at the Wayback Machine
AG, Novartis Pharma (25 June 2003). "Novartis Ophthalmics and Genentech announce development and commercialization agreement for age-related macular degeneration treatment, Lucentis(TM)". GlobeNewswire News Room (Press release). Retrieved 12 June 2023.

greekreporter.com

greece.greekreporter.com

"Greek Officials Hit Back at Novartis Bribery Allegations | GreekReporter.com". greece.greekreporter.com. 6 February 2018. Archived from the original on 1 November 2020. Retrieved 7 February 2018.

gsk.com

"GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business | GSK". www.gsk.com. 27 March 2018. Archived from the original on 27 November 2020. Retrieved 27 March 2018.

harvard.edu

ui.adsabs.harvard.edu

Macilwain, Colin (1 November 1998). "Berkeley teams up with Novartis in $50m plant genomics deal". Nature. 396 (6706): 5. Bibcode:1998Natur.396....5M. doi:10.1038/23772. ISSN 1476-4687. PMID 9817194.
Dalton, Rex (1 May 1999). "Berkeley dispute festers over biotech deal". Nature. 399 (6731): 5. Bibcode:1999Natur.399....5D. doi:10.1038/19807. ISSN 1476-4687. PMID 10331373.
Dalton, Rex (1 November 2003). "Syngenta ends plant-research deal with Berkeley". Nature. 426 (6964): 216. Bibcode:2003Natur.426..216D. doi:10.1038/426216a. ISSN 1476-4687. PMID 14628007.

huginonline.com

cws.huginonline.com

Novartis press release. 19 April 2006 Novartis acquisition of Chiron approved by Chiron shareholders Archived 20 October 2013 at the Wayback Machine

ifpma.org

"IFPMA Member List". Archived from the original on 7 February 2014. Retrieved 29 January 2021.

independent.co.uk

Magnus Grimond for The Independent. 8 March 1996 Ciba-Geigy and Sandoz to merge into pounds 40bn giant Archived 14 December 2013 at the Wayback Machine

indianexpress.com

"US sues Novartis again, says it bribed doctors for patents". Indian Express. Associated Press. Archived from the original on 1 June 2013. Retrieved 29 April 2013. Note: Link provides access to first of two pages; second page is here Archived 23 April 2020 at the Wayback Machine.
"Patent with a purpose, Prof. Shamnad Basheer, Indian Express, 3 April 2013". Archived from the original on 26 May 2013. Retrieved 29 January 2021.

archive.indianexpress.com

"US sues Novartis again, says it bribed doctors for patents". Indian Express. Associated Press. Archived from the original on 1 June 2013. Retrieved 29 April 2013. Note: Link provides access to first of two pages; second page is here Archived 23 April 2020 at the Wayback Machine.

indiatimes.com

articles.economictimes.indiatimes.com

"Patented drugs must be priced smartly". Archived from the original on 20 October 2013.

innomed-predtox.com

InnoMed PredTox Member Organizations (web page), InnoMed, archived from the original on 26 September 2008, retrieved 25 August 2008

japanherald.com

"Data manipulation by staff gets Novartis into legal mess in Japan". Japan Herald. Archived from the original on 29 August 2014. Retrieved 2 July 2014.

journalstar.com

Staff and wire reports for the Journal Star (Lincoln, Nebraska) 14 August 2013 Novartis reviews business; analyst urges selling OTC unit Archived 24 April 2019 at the Wayback Machine

judis.nic.in

Indian Supreme Court Decision paragraphs 5-6 Archived 6 July 2013 at the Wayback Machine
"Novartis v UoI, para 8-9". Archived from the original on 6 July 2013. Retrieved 29 January 2021.
"W.P. No.24759 of 2006". Archived from the original on 20 October 2013. Retrieved 29 January 2021.
"Novartis v UoI, Para 191". Archived from the original on 6 July 2013. Retrieved 29 January 2021.
"Novartis v UoI, Para 24-25". Archived from the original on 6 July 2013. Retrieved 29 January 2021.

justice.gov

"Novartis Pays Over $642 Million to Settle Allegations of Improper Payments to Patients and Physicians". www.justice.gov. U.S. Department of Justice. 1 July 2020. Retrieved 5 June 2024.
"United States Files Complaint Against Novartis Pharmaceuticals Corp. for Allegedly Paying Kickbacks to Doctors in Exchange for Prescribing Its Drugs". The United States Department of Justice. 26 April 2013. Archived from the original on 13 April 2014. Retrieved 26 April 2013.
"Novartis Hellas S.A.C.I. and Alcon Pte Ltd Agree to Pay over $233 Million Combined to Resolve Criminal FCPA Cases". www.justice.gov. 25 June 2020. Archived from the original on 13 January 2021. Retrieved 25 June 2020.

lawyerscollective.org

Staff, LawyersCollective. 6 September 2011 Novartis case: background and update – Supreme Court of India to recommence hearing Archived 21 October 2013 at the Wayback Machine

leadersleague.com

"Novartis set to buy Medicines Co. for $9.7 billion". Leaders League. Paris. 26 November 2019. Archived from the original on 5 August 2020. Retrieved 1 December 2019.

macrotrends.net

"Novartis AG Market Cap 2010-2022 | NVS". www.macrotrends.net. Archived from the original on 1 February 2023. Retrieved 1 February 2023.

marketwatch.com

Emily Church for MarketWatch 21 February 2005 Novartis in $8.29 billion generics deals: to buy Hexal and its US division Eon Labs Archived 20 October 2013 at the Wayback Machine
Emma Court (16 July 2018.) Novartis had 'longer and more detailed' relationship with Trump lawyer Michael Cohen, Senate report finds Archived 15 November 2020 at the Wayback Machine. MarketWatch. Retrieved 21 August 2018.

medscape.com

"FDA Approves Pasireotide for Cushing's Disease". Archived from the original on 30 July 2013.

nibr.com

"Innovation for the developing world". Archived from the original on 9 February 2014. Retrieved 29 January 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Macilwain, Colin (1 November 1998). "Berkeley teams up with Novartis in $50m plant genomics deal". Nature. 396 (6706): 5. Bibcode:1998Natur.396....5M. doi:10.1038/23772. ISSN 1476-4687. PMID 9817194.
Dalton, Rex (1 May 1999). "Berkeley dispute festers over biotech deal". Nature. 399 (6731): 5. Bibcode:1999Natur.399....5D. doi:10.1038/19807. ISSN 1476-4687. PMID 10331373.
Dalton, Rex (1 November 2003). "Syngenta ends plant-research deal with Berkeley". Nature. 426 (6964): 216. Bibcode:2003Natur.426..216D. doi:10.1038/426216a. ISSN 1476-4687. PMID 14628007.
Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.

novartis.com

"Research Locations". Novartis.
"Novartis Annual Report 2023" (PDF). Novartis AG. Archived (PDF) from the original on 31 January 2024. Retrieved 1 February 2024.
"Company history". Novartis.com. 15 December 2010. Archived from the original on 30 December 2010. Retrieved 2012-01-16.
Novartis Press Release. 8 April 2011 Stronger together: Novartis and Alcon creating the global leader in eye care Archived 20 October 2013 at the Wayback Machine
"Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms". Novartis. 18 October 2018. Archived from the original on 25 November 2020. Retrieved 18 October 2018.
"Share Ownership". Novartis. 12 June 2023. Archived from the original on 30 March 2023. Retrieved 12 June 2023.
"Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off". Novartis. Archived from the original on 12 June 2023. Retrieved 12 June 2023.
"Innovative Medicines". Novartis. Archived from the original on 12 June 2023. Retrieved 12 June 2023.
"Novartis Annual Report 2012" (PDF). Novartis. Archived from the original (PDF) on 28 February 2013. Retrieved 6 February 2018.
"Novartis Condensed financial report 2022 (PDF 0.5 MB)". Novartis. Archived from the original on 1 February 2023. Retrieved 1 February 2023.
"Novartis Institutes for BioMedical Research". Novartis. Archived from the original on 2 May 2014. Retrieved 29 January 2021.
Novartis Top 20 Products Annual Sales (Novartis Website), accessed 19 October 2013 Archived 28 April 2014 at the Wayback Machine
"Product Sales". Archived from the original on 7 August 2023. Retrieved 7 August 2023.
"Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease". Novartis. Archived from the original on 20 November 2020. Retrieved 16 October 2019.
"FDA approves Novartis Scemblix® (Asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia". Archived from the original on 29 October 2021. Retrieved 15 July 2024.
"US Department of Health and Human Services awards Novartis USD 486 million contract to build manufacturing facility for pandemic flu vaccine" (Press release). Novartis. 15 January 2009. Archived from the original on 3 June 2010. Retrieved 13 November 2009.
"Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, reaches settlement agreement with US Attorney's Office" (press release). Novartis. 30 September 2010. Media Releases. Archived from the original on 17 October 2013. Retrieved 16 January 2012.

nps.org.au

"Sertraline Sandoz Tablet". NPS MedicineWise. Archived from the original on 9 January 2019. Retrieved 9 January 2019.

nysun.com

"Albert Hofmann, 102, Invented LSD - The New York Sun". Nysun.com. Archived from the original on 20 October 2013. Retrieved 23 October 2013.

nytimes.com

"CIA considered big LSD purchase". The New York Times. 5 August 1976. Archived from the original on 24 May 2022. Retrieved 25 May 2022.
Glenn Collins for The New York Times. 7 March 1996 2 Swiss Drug Giants In a Surprise Merger To Be 2d in World Archived 8 December 2020 at the Wayback Machine
Andrew Ross Sorkin for The New York Times. 3 December 1999 AstraZeneca and Novartis To Shed Agricultural Units Archived 11 September 2020 at the Wayback Machine Accessed 27 May 2013
Andrew Martin and Andrew Ross Sorkin for The New York Times. 13 April 2007 Nestlé Agrees to Buy Gerber From Novartis Archived 23 November 2020 at the Wayback Machine
Harris, Gardiner; Thomas, Katie (1 April 2013). "Top Court in India Rejects Novartis Drug Patent". The New York Times. Archived from the original on 30 May 2020. Retrieved 1 April 2013.
McNeil, Donald G. Jr. (28 June 2010). "The Drug Industry: GlaxoSmithKline, Merck and Novartis Again Rank Highest on Access to Poor". The New York Times. ISSN 0362-4331. Archived from the original on 10 September 2020. Retrieved 21 January 2020.
Wilson, Duff (30 September 2010). "Novartis Settles Off-Label Marketing Case". The New York Times. Archived from the original on 16 November 2018. Retrieved 16 January 2012.
"U.S. Sues Novartis Again, Accusing It of Kickbacks". The New York Times. 26 April 2013. Archived from the original on 5 October 2019. Retrieved 27 April 2013.
Andrew Pollack for The New York Times. 28 April 2011 Cheaper Drug to Treat Eye Disease Is Effective Archived 16 September 2018 at the Wayback Machine
"Greek Govt Alleges Official Ties to Drug Bribery Scandal". The New York Times. Associated Press. 5 February 2018. ISSN 0362-4331. Archived from the original on 16 November 2018. Retrieved 7 February 2018.

dealbook.nytimes.com

De la Merced, Michael J. (2 May 2012). "Novartis to Buy Fougera Pharmaceuticals for $1.5 Billion". DealB%k. The New York Times. Archived from the original on 5 August 2020. Retrieved 25 January 2020.

patents.google.com

"Patent US2438259 - D-lysergic acid diethyl amide". google.com. Archived from the original on 9 June 2016. Retrieved 11 November 2016.
"Patent US5521184 - Pyrimidine derivatives and processes for the preparation thereof". google.com. Archived from the original on 15 December 2020. Retrieved 11 November 2016.

pharmaceutical-technology.com

Philpott, Jenna (19 November 2024). "Novartis strengthens radiopharma leadership with Ratio Therapeutics deal". Pharmaceutical Technology. Retrieved 25 November 2024.
"GSK Pharma completes acquisition of Novartis Healthcare's vaccines business". 30 September 2015. Archived from the original on 5 January 2021. Retrieved 21 January 2020.

pharmafile.com

Ben Adams for Pharmafile. 26 July 2012 Lucentis price cut ends PCT-Novartis dispute Archived 19 October 2013 at the Wayback Machine

pharmaphorum.com

"A history of Novartis -". pharmaphorum.com. 20 September 2013. Archived from the original on 2 December 2020. Retrieved 21 January 2020.

pharmatimes.com

Kevin Grogan for PharmaTimes. 27 February 2012 Novartis explains stance over India patent law challenge Archived 16 December 2014 at the Wayback Machine
Ben Adams for Pharma Times. 3 October 2012. Novartis to drop legal case against NHS body Archived 19 October 2013 at the Wayback Machine

phrma.org

"404". www.phrma.org. Archived from the original on 6 October 2013. Retrieved 29 January 2021. {{cite web}}: Cite uses generic title (help)

pitchengine.com

"IPCI: FDA Approves First Focalin XR ANDA; Positive Incremental Step Toward Approval and October Launch for IPCI". Archived from the original on 20 October 2013.

pmlive.com

"Novartis and Dren Bio enter bispecific antibody partnership worth up to $3bn - PMLiVE". pmlive.com. 25 July 2024. Archived from the original on 1 August 2024. Retrieved 25 July 2024.
"Novartis restructures organisation to support growth and innovation". PMLive. 4 April 2022. Archived from the original on 12 June 2023. Retrieved 12 June 2023.

proclinical.com

"Who are the top 10 pharmaceutical companies in the world (2022)? | Proclinical Blogs". Proclinical. Archived from the original on 6 February 2023. Retrieved 11 July 2023.

reuters.com

Thomasson, Emma (4 January 2010). "Novartis seeks to buy rest of Alcon for $39 billion". Reuters. Archived from the original on 20 October 2013. Retrieved 4 January 2010.
Reid, Katie (13 January 2012), Hans-Juergen Peters and Mike Nesbit (ed.), Novartis cuts 2,000 U.S. jobs after drug setback, Reuters, reuters.com, archived from the original on 10 January 2014, retrieved 2012-01-15
John Miller (3 November 2017). "Novartis to buy French cancer specialist AAA for $3.9 billion". Reuters. Retrieved 17 December 2023.
"Novartis buys neuroscience company Cadent for up to $770 million". Reuters. 17 December 2020. Archived from the original on 4 February 2021. Retrieved 29 January 2021 – via www.reuters.com.
Mitra, Sinchita (22 December 2021). "Novartis buys Gyroscope for $1.5 BLN to add new retinal gene therapy". Reuters. Archived from the original on 23 December 2021. Retrieved 23 December 2021.
Burger, Ludwig (12 June 2023). "Novartis buys Chinook for $3.5 billion in race to treat rare kidney disease". Reuters. Archived from the original on 13 June 2023. Retrieved 11 July 2023.
"Bausch + Lomb to buy Novartis dry-eye drug for $1.75 bln". Reuters. 30 June 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
Burger, Ludwig (15 September 2023). "Novartis shareholders vote in favour of Sandoz spin-off". Reuters. Archived from the original on 26 September 2023. Retrieved 18 September 2023.
"Sandoz to initially join Swiss mid-cap index after listing - SIX exchange". Reuters. 13 September 2023. Archived from the original on 4 October 2023. Retrieved 19 September 2023.
Veyet, Tristan; Illien, Noele (4 October 2023). "Novartis completes Sandoz spinoff". Reuters. Archived from the original on 4 October 2023. Retrieved 4 October 2023.
"Novartis to acquire cancer-centric MorphoSys for $2.9 bln". Reuters. 5 February 2024. Retrieved 5 February 2024.
"Novartis's Alcon spinoff ousts Baer from Swiss benchmark SMI". Reuters. 3 April 2019. Archived from the original on 12 June 2023. Retrieved 12 June 2023.
Grover, Natalie (25 August 2022). "Novartis to spin off generics business Sandoz next year". Reuters. Archived from the original on 12 June 2023. Retrieved 12 June 2023.
"Novartis, U.S. partner plan remote trials to boost participation". Reuters. 7 March 2018. Archived from the original on 9 November 2020. Retrieved 15 March 2018.
Copley, Caroline; Hirschler, Ben (24 April 2012), Potter, Mark (ed.), Novartis challenges UK Avastin use in eye disease, Reuters, archived from the original on 22 May 2013, retrieved 2012-04-29

uk.reuters.com

"GSK buys out Novartis in $13 billion consumer healthcare shake-up". Reuters. 27 March 2018. Archived from the original on 5 August 2020. Retrieved 9 January 2019.
"Novartis bets big on gene therapy with $8.7 billion AveXis deal". Reuters. 9 April 2018. Archived from the original on 5 August 2020. Retrieved 9 January 2019.
"Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash". Reuters. 18 October 2018. Archived from the original on 5 August 2020. Retrieved 9 January 2019.
"Novartis pushes deeper into nuclear medicine with $2.1 billion deal". Reuters. 18 October 2018. Archived from the original on 5 August 2020. Retrieved 9 January 2019.
"Novartis to buy France's CellforCure to boost cell, gene therapy". Reuters. 20 December 2018. Archived from the original on 6 August 2020. Retrieved 20 December 2018.
Reuters, 21 October 2010 Biosimilars take off at Novartis generics unit Archived 20 October 2013 at the Wayback Machine

sandiegouniontribune.com

Freeman, Mike (17 July 2023). "San Diego biotech that's trying to cure hard-to-treat diseases is acquired for $500M". The San Diego Union-Tribune. Archived from the original on 21 August 2023. Retrieved 21 August 2023.

sciencemuseumgroup.org.uk

collection.sciencemuseumgroup.org.uk

"J R Geigy SA | Science Museum Group Collection". collection.sciencemuseumgroup.org.uk. Archived from the original on 5 August 2020. Retrieved 29 January 2021.
"J. R. Geigy Soc. An. | Science Museum Group Collection". collection.sciencemuseumgroup.org.uk. Archived from the original on 5 August 2020. Retrieved 29 January 2021.

scribd.com

Note: The Indian patent application No.1602/MAS/1998 does not appear to be publicly available. However, according to the decision of the IPAB on 26 June 2009 (page 27) discussed below, "The Appellant's application under the PCT was substantially on the same invention as had been made in India." Archived 22 October 2013 at the Wayback Machine
"IPAB Order Dated 26-Jun-2009 in Novartis v. Union of India | Patent Application | Patent". Scribd. Archived from the original on 22 October 2013. Retrieved 29 January 2021.

seattletimes.com

"Novartis 1Q profit jumps 12 percent as heart drug sales soar". Business. The Seattle Times. Associated Press. 19 April 2018. Archived from the original on 5 August 2020. Retrieved 20 April 2018.

sec.gov

"SEC 2010". Archived from the original on 6 August 2020. Retrieved 9 January 2020.
"Press release issued jointly by Genentech, Inc. and Tanox Inc". www.sec.gov. Archived from the original on 12 June 2023. Retrieved 12 June 2023.
"20-F". www.sec.gov. p. 63. Archived from the original on 5 August 2020. Retrieved 11 March 2019.
"SEC.gov | SEC Charges Novartis AG with FCPA Violations". www.sec.gov. Archived from the original on 18 January 2021. Retrieved 25 June 2020.

senate.gov

finance.senate.gov

White House Access for Sale: Michael Cohen, Novartis and the bid to sell access to the Trump administration Archived 13 November 2020 at the Wayback Machine. Retrieved 21 August 2018.

seqirus.com

"CSL completes Novartis influenza vaccine acquisition in Germany". www.seqirus.com. Archived from the original on 5 August 2020. Retrieved 9 January 2019.

spicyip.com

Shamnad Basheer for Spicy IP 11 March 2006 First Mailbox Opposition (Gleevec) Decided in India Archived 21 October 2013 at the Wayback Machine

spicyipindia.blogspot.co.uk

"Supreme Court rejects bid by Novartis to patent Glivec". Archived from the original on 17 December 2013.

strategy-business.com

Lawrence M. Fisher for strategy + business. 1 April 1998 Post-Merger Integration: How Novartis Became No. 1 Archived 20 May 2013 at the Wayback Machine

swissinfo.ch

Keystone-SDA/jdp (22 September 2022). "Novartis sets sights on high-value medicines and US market". SWI swissinfo.ch. Retrieved 12 June 2023.

telegraphindia.com

"Shift in Novartis Strategy, The Telegraph". Archived from the original on 11 May 2013. Retrieved 29 January 2021.

tevapharm.com

ir.tevapharm.com

Teva press release. 30 January 2007 Teva Receives Approval for Generic Focalin™ Tablets Archived 13 August 2020 at the Wayback Machine

thefreelibrary.com

Staff, PRNewsWire. 13 November 2000. Syngenta Begins Trading on the New York Stock Exchange Accessed 27 May 2013 ^{[dead link‍]}

thehindubusinessline.com

Datta, P. T. Jyothi (18 December 2015). "Novartis consolidates global services operations at Hyderabad centre". The Hindu BusinessLine. Archived from the original on 8 November 2020. Retrieved 6 February 2020.

thejakartapost.com

"Novartis to cut almost 2,000 US jobs this year", The Jakarta Post, Associated Press, jakartapost.com, 13 January 2012, archived from the original on 25 May 2013, retrieved 2012-01-15

time.com

"Medicine: Dream Stuff". Time. 28 June 1954. Archived from the original on 27 August 2013.

washingtonpost.com

Voris, Bob Van (14 July 2010). "Novartis Reaches $152.5 Million Sex-Bias Settlement". Archived from the original on 18 May 2018. Retrieved 29 January 2021 – via www.washingtonpost.com.

web.archive.org

"Novartis 1Q profit jumps 12 percent as heart drug sales soar". Business. The Seattle Times. Associated Press. 19 April 2018. Archived from the original on 5 August 2020. Retrieved 20 April 2018.
"Novartis Annual Report 2023" (PDF). Novartis AG. Archived (PDF) from the original on 31 January 2024. Retrieved 1 February 2024.
"Who are the top 10 pharmaceutical companies in the world (2022)? | Proclinical Blogs". Proclinical. Archived from the original on 6 February 2023. Retrieved 11 July 2023.
"Top 25 Pharma & BioPharma in 2022 | Contract Pharma". www.contractpharma.com. Archived from the original on 6 February 2023. Retrieved 6 February 2023.
"BIO Member Directory | BIO". www.bio.org. Archived from the original on 30 September 2022. Retrieved 1 March 2024.
"IFPMA Member List". Archived from the original on 7 February 2014. Retrieved 29 January 2021.
"404". www.phrma.org. Archived from the original on 6 October 2013. Retrieved 29 January 2021. {{cite web}}: Cite uses generic title (help)
"A history of Novartis -". pharmaphorum.com. 20 September 2013. Archived from the original on 2 December 2020. Retrieved 21 January 2020.
"Novartis AG | Swiss company". Encyclopedia Britannica. Archived from the original on 27 October 2020. Retrieved 21 January 2020.
"J R Geigy SA | Science Museum Group Collection". collection.sciencemuseumgroup.org.uk. Archived from the original on 5 August 2020. Retrieved 29 January 2021.
"J. R. Geigy Soc. An. | Science Museum Group Collection". collection.sciencemuseumgroup.org.uk. Archived from the original on 5 August 2020. Retrieved 29 January 2021.
"Ciba-Geigy AG | Swiss pharmaceutical company". Encyclopedia Britannica. Archived from the original on 10 October 2017. Retrieved 21 January 2020.
"Company history". Novartis.com. 15 December 2010. Archived from the original on 30 December 2010. Retrieved 2012-01-16.
"Albert Hofmann, 102, Invented LSD - The New York Sun". Nysun.com. Archived from the original on 20 October 2013. Retrieved 23 October 2013.
"Patent US2438259 - D-lysergic acid diethyl amide". google.com. Archived from the original on 9 June 2016. Retrieved 11 November 2016.
"Albert Hofmann: LSD - My Problem Child: Use of LSD in Psychiatry". Flashback.se. Archived from the original on 7 July 2006. Retrieved 16 January 2012.
"Medicine: Dream Stuff". Time. 28 June 1954. Archived from the original on 27 August 2013.
"CIA considered big LSD purchase". The New York Times. 5 August 1976. Archived from the original on 24 May 2022. Retrieved 25 May 2022.
Magnus Grimond for The Independent. 8 March 1996 Ciba-Geigy and Sandoz to merge into pounds 40bn giant Archived 14 December 2013 at the Wayback Machine
Glenn Collins for The New York Times. 7 March 1996 2 Swiss Drug Giants In a Surprise Merger To Be 2d in World Archived 8 December 2020 at the Wayback Machine
Lawrence M. Fisher for strategy + business. 1 April 1998 Post-Merger Integration: How Novartis Became No. 1 Archived 20 May 2013 at the Wayback Machine
Andrew Ross Sorkin for The New York Times. 3 December 1999 AstraZeneca and Novartis To Shed Agricultural Units Archived 11 September 2020 at the Wayback Machine Accessed 27 May 2013
Press Release, Novartis. 21 January 2003 Novartis to Unite Its Generics Businesses Under One Single Global Brand: Sandoz Archived 17 October 2013 at the Wayback Machine
Emily Church for MarketWatch 21 February 2005 Novartis in $8.29 billion generics deals: to buy Hexal and its US division Eon Labs Archived 20 October 2013 at the Wayback Machine
Novartis press release. 19 April 2006 Novartis acquisition of Chiron approved by Chiron shareholders Archived 20 October 2013 at the Wayback Machine
Staff, Biosimilars News. 15 August 2011 Biosimilars approved in Europe Archived 20 October 2013 at the Wayback Machine
Andrew Martin and Andrew Ross Sorkin for The New York Times. 13 April 2007 Nestlé Agrees to Buy Gerber From Novartis Archived 23 November 2020 at the Wayback Machine
"Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL®". www.worldpharmanews.com. Archived from the original on 13 November 2009. Retrieved 29 January 2021.
Thomasson, Emma (4 January 2010). "Novartis seeks to buy rest of Alcon for $39 billion". Reuters. Archived from the original on 20 October 2013. Retrieved 4 January 2010.
Novartis Press Release. 8 April 2011 Stronger together: Novartis and Alcon creating the global leader in eye care Archived 20 October 2013 at the Wayback Machine
"Can Novartis' CEO resist going for a megamerger with cash from asset sales? - FiercePharma". www.fiercepharma.com. 30 May 2017. Archived from the original on 30 October 2020. Retrieved 6 February 2018.
Maclucas, Neil (24 January 2011). "Novartis to Buy Genoptix for $470 Million". Health. The Wall Street Journal. Archived from the original on 10 January 2014.
"Novartis to cut almost 2,000 US jobs this year", The Jakarta Post, Associated Press, jakartapost.com, 13 January 2012, archived from the original on 25 May 2013, retrieved 2012-01-15
Reid, Katie (13 January 2012), Hans-Juergen Peters and Mike Nesbit (ed.), Novartis cuts 2,000 U.S. jobs after drug setback, Reuters, reuters.com, archived from the original on 10 January 2014, retrieved 2012-01-15
De la Merced, Michael J. (2 May 2012). "Novartis to Buy Fougera Pharmaceuticals for $1.5 Billion". DealB%k. The New York Times. Archived from the original on 5 August 2020. Retrieved 25 January 2020.
Harris, Gardiner; Thomas, Katie (1 April 2013). "Top Court in India Rejects Novartis Drug Patent". The New York Times. Archived from the original on 30 May 2020. Retrieved 1 April 2013.
"US sues Novartis again, says it bribed doctors for patents". Indian Express. Associated Press. Archived from the original on 1 June 2013. Retrieved 29 April 2013. Note: Link provides access to first of two pages; second page is here Archived 23 April 2020 at the Wayback Machine.
Staton, Tracy (21 January 2014). "Novartis to cut 500 Swiss pharma jobs, then staff up in OTC, generics". FiercePharma. Questex. Archived from the original on 26 March 2014. Retrieved 19 February 2014.
Johnson, Michael (18 January 2014). "Novartis acquires CoStim Pharmaceuticals". Drug Store News. Lebhar-Friedman. Archived from the original on 25 February 2014. Retrieved 19 February 2014.
"Novartis Buys Ex-U.S. Rights to Ophthotech's Fovista for Up to $1B". News | Industry Watch. Genetic Engineering & Biotechnology News (Paper). Vol. 34, no. 12. Mary Ann Liebert. 15 June 2014. p. 8. Archived from the original on 5 August 2020. Retrieved 25 January 2020.
"Ophthotech Pockets $50M Milestone from Novartis for AMD Treatment". GEN News Highlights. Genetic Engineering & Biotechnology News. Mary Ann Liebert. 8 September 2014. Archived from the original on 11 May 2018. Retrieved 14 September 2014.
BBC (22 April 2014). "Novartis and GSK exchange assets". BBC. Archived from the original on 29 April 2014. Retrieved 22 April 2014.
"Novartis Takes Stake in Gamida with Option to Fully Buy". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 19 August 2014. Archived from the original on 11 May 2018. Retrieved 25 January 2020.
"Novartis Selling Flu Vaccine Business to CSL for $275M". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 27 October 2014. Archived from the original on 3 September 2018. Retrieved 25 January 2020.
"Array BioPharma Completes Deal with Novartis for 2 Cancer Compounds". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 2 March 2015. Archived from the original on 2 July 2017. Retrieved 25 January 2020.
"Novartis Sells RNAi R&D Portfolio to Arrowhead in $35M Agreement". GEN News Highlights. Genetic Engineering & Biotechnology News. Mary Ann Liebert. 5 March 2015. Archived from the original on 9 April 2015. Retrieved 8 June 2016. Note: appears on page 10 of 1 April 2015 print issue.
"Novartis Acquires Spinifex for $200M+". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 29 June 2015. Archived from the original on 4 March 2016. Retrieved 25 January 2020.
Helfand, Cindy (21 August 2015). "Novartis shells out up to $1B to test GSK's Arzerra in MS". FiercePharma. Questex. Archived from the original on 4 April 2016. Retrieved 25 January 2020.
"Novartis Acquires All Remaining Rights to GSK's Ofatumumab". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 21 August 2015. Archived from the original on 23 August 2015.
"Novartis Buys Admune; Licenses Palobiofarma, XOMA Compounds". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 21 October 2015. Archived from the original on 17 August 2017. Retrieved 25 January 2020.
"Novartis Acquires Selexys Pharmaceuticals - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN". 21 November 2016. Archived from the original on 30 October 2018. Retrieved 21 November 2016.
"Novartis Buys Encore Vision for Presbyopia Therapy Eyedrops - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN". 20 December 2016. Archived from the original on 21 December 2016. Retrieved 21 December 2016.
Terry, Mark (19 December 2016). "Novartis AG Snaps Up Mid-Stage Eczema Rival". BioSpace. Archived from the original on 6 August 2020. Retrieved 29 October 2018.
"GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business | GSK". www.gsk.com. 27 March 2018. Archived from the original on 27 November 2020. Retrieved 27 March 2018.
"GSK buys out Novartis in $13 billion consumer healthcare shake-up". Reuters. 27 March 2018. Archived from the original on 5 August 2020. Retrieved 9 January 2019.
"Novartis bets big on gene therapy with $8.7 billion AveXis deal". Reuters. 9 April 2018. Archived from the original on 5 August 2020. Retrieved 9 January 2019.
"Novartis licenses out unwanted GlaxoSmithKline cancer drugs to Chinese biotech | FierceBiotech". www.fiercebiotech.com. August 2018. Archived from the original on 5 August 2020. Retrieved 3 August 2018.
"China's Laekna Inks Two-Drug Deal with Novartis | BioSpace". BioSpace. Archived from the original on 5 August 2020. Retrieved 3 August 2018.
"Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash". Reuters. 18 October 2018. Archived from the original on 5 August 2020. Retrieved 9 January 2019.
"Novartis pushes deeper into nuclear medicine with $2.1 billion deal". Reuters. 18 October 2018. Archived from the original on 5 August 2020. Retrieved 9 January 2019.
"Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms". Novartis. 18 October 2018. Archived from the original on 25 November 2020. Retrieved 18 October 2018.
"Novartis to buy France's CellforCure to boost cell, gene therapy". Reuters. 20 December 2018. Archived from the original on 6 August 2020. Retrieved 20 December 2018.
"Out From Under Novartis, Alcon Is Its Own Company Now". BioSpace. 9 April 2019. Archived from the original on 23 September 2020. Retrieved 10 April 2019.
Neville, Sarah; Waters, Richard (October 2019). "Novartis and Microsoft join forces to develop drugs using AI". Financial Times. Archived from the original on 4 October 2020. Retrieved 5 November 2019.
"Sandoz Boosts Toehold in Japan with Aspen Acquisition". BioSpace. 11 November 2019. Archived from the original on 6 August 2020. Retrieved 4 May 2020.
Terry, Mark (25 November 2019). "Novartis Buys The Medicines Company: A $9.7 Billion Gamble on a PCSK9 Cholesterol Drug". BioSpace. Urbandale, Iowa. Archived from the original on 6 August 2020. Retrieved 1 December 2019.
"Novartis set to buy Medicines Co. for $9.7 billion". Leaders League. Paris. 26 November 2019. Archived from the original on 5 August 2020. Retrieved 1 December 2019.
"Amblyotech, A Digital Therapeutics Company, Announces It Has Been Acquired by Novartis". BioSpace. Archived from the original on 6 August 2020. Retrieved 4 May 2020.
"Pharmaceutical giants fined record €444 million for 'abusive practices'". The Brussels Times. 9 September 2020. Archived from the original on 9 October 2020. Retrieved 13 September 2020.
"BuyNTech buys Novartis site to boost EU vaccine production". Financial Times. 17 September 2020. Archived from the original on 15 January 2021. Retrieved 21 September 2020.
"Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company". BioSpace. Archived from the original on 7 November 2020. Retrieved 29 January 2021.
"Novartis Expands Footprint in Gene and Cell Therapy with Vedere Bio Acquisition". BioSpace. 29 October 2020. Archived from the original on 25 November 2020. Retrieved 29 January 2021.
Global Legal Chronicle Archived 11 November 2020 at the Wayback Machine Molecular Partners Option and License Agreement with Novartis (30 October 2020)
"Cadent Therapeutics Enters Agreement to be Acquired by Novartis". BioSpace. Archived from the original on 5 February 2021. Retrieved 29 January 2021.
"Novartis buys neuroscience company Cadent for up to $770 million". Reuters. 17 December 2020. Archived from the original on 4 February 2021. Retrieved 29 January 2021 – via www.reuters.com.
"Novartis Adds to Optogenetics Portfolio with Arctos Medical Buy". 21 September 2021. Archived from the original on 23 September 2021. Retrieved 23 September 2021.
Mitra, Sinchita (22 December 2021). "Novartis buys Gyroscope for $1.5 BLN to add new retinal gene therapy". Reuters. Archived from the original on 23 December 2021. Retrieved 23 December 2021.
"Novartis vet is getting another shot at mTOR following the implosion of a longevity pioneer". Endpoints. 16 February 2022. Archived from the original on 14 March 2022. Retrieved 14 March 2022.
Burger, Ludwig (12 June 2023). "Novartis buys Chinook for $3.5 billion in race to treat rare kidney disease". Reuters. Archived from the original on 13 June 2023. Retrieved 11 July 2023.
Freeman, Mike (17 July 2023). "San Diego biotech that's trying to cure hard-to-treat diseases is acquired for $500M". The San Diego Union-Tribune. Archived from the original on 21 August 2023. Retrieved 21 August 2023.
"Bausch + Lomb to buy Novartis dry-eye drug for $1.75 bln". Reuters. 30 June 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
Burger, Ludwig (15 September 2023). "Novartis shareholders vote in favour of Sandoz spin-off". Reuters. Archived from the original on 26 September 2023. Retrieved 18 September 2023.
Kuchler, Hannah (18 August 2023). "Novartis plans to spin off Sandoz in October". Financial Times. Archived from the original on 4 October 2023. Retrieved 19 September 2023.
"Sandoz to initially join Swiss mid-cap index after listing - SIX exchange". Reuters. 13 September 2023. Archived from the original on 4 October 2023. Retrieved 19 September 2023.
Veyet, Tristan; Illien, Noele (4 October 2023). "Novartis completes Sandoz spinoff". Reuters. Archived from the original on 4 October 2023. Retrieved 4 October 2023.
"JB Chemicals acquires around 15 opthalmology drugs from Novartis for ₹1,089 crore". CNBCTV18. 19 December 2023. Archived from the original on 19 December 2023. Retrieved 19 December 2023.
"Madrid Yearly Review 2024" (PDF). p. 22. Archived (PDF) from the original on 25 June 2024. Retrieved 18 September 2024.
"German regulators approve Novartis deal to buy drugmaker Morphosys". Yahoo News. 12 March 2024. Archived from the original on 12 March 2024. Retrieved 10 April 2024.
"Novartis to buy Mariana Oncology in radiopharmaceutical expansion". Yahoo Finance. 2 May 2024. Archived from the original on 3 May 2024. Retrieved 3 May 2024.
"Novartis and Dren Bio enter bispecific antibody partnership worth up to $3bn - PMLiVE". pmlive.com. 25 July 2024. Archived from the original on 1 August 2024. Retrieved 25 July 2024.
"Novartis hopes for better luck with bispecifics via $150M upfront Dren Bio deal". Fiercebiotech. Archived from the original on 27 July 2024. Retrieved 25 July 2024.
"Share Ownership". Novartis. 12 June 2023. Archived from the original on 30 March 2023. Retrieved 12 June 2023.
"SEC 2010". Archived from the original on 6 August 2020. Retrieved 9 January 2020.
Roland, Denise (17 May 2016). "Novartis Pharmaceuticals Head to Depart Amid Restructuring". Wall Street Journal. Archived from the original on 5 August 2020. Retrieved 9 January 2020.
"Novartis's Alcon spinoff ousts Baer from Swiss benchmark SMI". Reuters. 3 April 2019. Archived from the original on 12 June 2023. Retrieved 12 June 2023.
"Alcon to Officially Spin out From Novartis on April 9". BioSpace. 22 March 2019. Archived from the original on 6 August 2020. Retrieved 9 January 2020.
"Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off". Novartis. Archived from the original on 12 June 2023. Retrieved 12 June 2023.
"Alcon Debuts as Independent, Publicly Traded Company". investor.alcon.com. Archived from the original on 12 June 2023. Retrieved 12 June 2023.
Grover, Natalie (25 August 2022). "Novartis to spin off generics business Sandoz next year". Reuters. Archived from the original on 12 June 2023. Retrieved 12 June 2023.
"Innovative Medicines". Novartis. Archived from the original on 12 June 2023. Retrieved 12 June 2023.
"Novartis restructures organisation to support growth and innovation". PMLive. 4 April 2022. Archived from the original on 12 June 2023. Retrieved 12 June 2023.
"JPM23: Novartis takes sweeping approach to 'US-first' mindset, exec says". Archived from the original on 12 June 2023. Retrieved 12 June 2023.
"Novartis Annual Report 2012" (PDF). Novartis. Archived from the original (PDF) on 28 February 2013. Retrieved 6 February 2018.
"Novartis AG to Hold On to Its 33% Stake in Roche—For Now". BioSpace. 12 October 2017. Archived from the original on 1 November 2020. Retrieved 10 January 2020.
"Avastin vs Lucentis" (PDF). Archived (PDF) from the original on 6 August 2020. Retrieved 29 January 2021.
"Press release issued jointly by Genentech, Inc. and Tanox Inc". www.sec.gov. Archived from the original on 12 June 2023. Retrieved 12 June 2023.
"Novartis slashing thousands more jobs in global reorganization, shifting many to India". FiercePharma. 2 February 2014. Archived from the original on 2 August 2019. Retrieved 4 February 2015.
Datta, P. T. Jyothi (18 December 2015). "Novartis consolidates global services operations at Hyderabad centre". The Hindu BusinessLine. Archived from the original on 8 November 2020. Retrieved 6 February 2020.
"Top 10 Pharma Companies of 2019". 18 November 2019. Archived from the original on 11 November 2020. Retrieved 29 January 2021.
"Novartis Snags Remaining 23% Stake in Alcon with $12.9B Cash and Share Deal | GEN - Genetic Engineering and Biotechnology News". GEN - Genetic Engineering and Biotechnology News. 15 December 2010. Archived from the original on 13 August 2020. Retrieved 14 January 2020.
Reuters, 21 October 2010 Biosimilars take off at Novartis generics unit Archived 20 October 2013 at the Wayback Machine
Staff, Generics and Biosimilars Initiative, 9 November 2012 Sandoz starts phase III US trial for biosimilar epoetin alfa Archived 20 October 2013 at the Wayback Machine
"20-F". www.sec.gov. p. 63. Archived from the original on 5 August 2020. Retrieved 11 March 2019.
Morse, Andrew (11 November 2013). "Novartis Sells Unit for $1.68 Billion". Wall Street Journal. ISSN 0099-9660. Archived from the original on 5 August 2020. Retrieved 21 January 2020.
"CSL completes Novartis influenza vaccine acquisition in Germany". www.seqirus.com. Archived from the original on 5 August 2020. Retrieved 9 January 2019.
"GSK Pharma completes acquisition of Novartis Healthcare's vaccines business". 30 September 2015. Archived from the original on 5 January 2021. Retrieved 21 January 2020.
"Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV". finance.yahoo.com. 28 March 2018. Archived from the original on 5 August 2020. Retrieved 11 March 2019.
Staff and wire reports for the Journal Star (Lincoln, Nebraska) 14 August 2013 Novartis reviews business; analyst urges selling OTC unit Archived 24 April 2019 at the Wayback Machine
Staff, WHO. Access to Medicine Index, 2012
"Novartis AG". Access to Medicine Foundation. Archived from the original on 30 January 2021. Retrieved 22 November 2019.
McNeil, Donald G. Jr. (28 June 2010). "The Drug Industry: GlaxoSmithKline, Merck and Novartis Again Rank Highest on Access to Poor". The New York Times. ISSN 0362-4331. Archived from the original on 10 September 2020. Retrieved 21 January 2020.
"Novartis Condensed financial report 2022 (PDF 0.5 MB)". Novartis. Archived from the original on 1 February 2023. Retrieved 1 February 2023.
"Novartis AG Market Cap 2010-2022 | NVS". www.macrotrends.net. Archived from the original on 1 February 2023. Retrieved 1 February 2023.
Ross, Casey (27 October 2010). "Novartis doubles plan for Cambridge". The Boston Globe. Archived from the original on 3 November 2012. Retrieved 31 October 2010.
"Novartis Institutes for BioMedical Research". Novartis. Archived from the original on 2 May 2014. Retrieved 29 January 2021.
"Innovation for the developing world". Archived from the original on 9 February 2014. Retrieved 29 January 2021.
InnoMed PredTox Member Organizations (web page), InnoMed, archived from the original on 26 September 2008, retrieved 25 August 2008
Innovative Medicines Initiative, ed. (2008), "IMI-GB-018v2-24042008-CallTopics.pdf", IMI 1st Call 2008: Information Package (ZIP archive), European Commission, archived from the original (PDF) on 24 September 2015, retrieved 16 January 2012
"Novartis, U.S. partner plan remote trials to boost participation". Reuters. 7 March 2018. Archived from the original on 9 November 2020. Retrieved 15 March 2018.
Novartis Top 20 Products Annual Sales (Novartis Website), accessed 19 October 2013 Archived 28 April 2014 at the Wayback Machine
Teva press release. 30 January 2007 Teva Receives Approval for Generic Focalin™ Tablets Archived 13 August 2020 at the Wayback Machine
"IPCI: FDA Approves First Focalin XR ANDA; Positive Incremental Step Toward Approval and October Launch for IPCI". Archived from the original on 20 October 2013.
"Product Sales". Archived from the original on 7 August 2023. Retrieved 7 August 2023.
Novartis official 2007 product sales From Internet Archive; archive date 13 November 2007
Commissioner, Office of the (11 September 2019). "FDA approves new oral drug to treat multiple sclerosis". FDA. Archived from the original on 9 February 2021. Retrieved 16 October 2019.
"Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease". Novartis. Archived from the original on 20 November 2020. Retrieved 16 October 2019.
"FDA approves Novartis Scemblix® (Asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia". Archived from the original on 29 October 2021. Retrieved 15 July 2024.
"Sertraline Sandoz Tablet". NPS MedicineWise. Archived from the original on 9 January 2019. Retrieved 9 January 2019.
"EU/3/09/671 | European Medicines Agency". Archived from the original on 4 February 2014. Retrieved 29 January 2021.
"FDA Approves Pasireotide for Cushing's Disease". Archived from the original on 30 July 2013.
"NICE Backs Novartis's Tasigna For CML, Rejects BMS's Sprycel", The Wall Street Journal, online.wsj.com, 12 January 2012, archived from the original on 17 May 2013, retrieved 2012-01-15
Teva Press Release 12 December 2007 Teva Announces Approval of Generic Trileptal Tablets Archived 20 October 2013 at the Wayback Machine
"US Department of Health and Human Services awards Novartis USD 486 million contract to build manufacturing facility for pandemic flu vaccine" (Press release). Novartis. 15 January 2009. Archived from the original on 3 June 2010. Retrieved 13 November 2009.
Staton, Tracy (22 April 2014). "Novartis, GSK team up in consumer JV to save big money, gain big scale". FiercePharma. Questex Media Group. Archived from the original on 26 October 2020. Retrieved 16 May 2016.
Note: The Indian patent application No.1602/MAS/1998 does not appear to be publicly available. However, according to the decision of the IPAB on 26 June 2009 (page 27) discussed below, "The Appellant's application under the PCT was substantially on the same invention as had been made in India." Archived 22 October 2013 at the Wayback Machine
"Crystal Modification of a N-Phenyl-2-Pyrimidineamine Derivative, Processes for Its Manufacture and Its Use". Archived from the original on 22 October 2013. Retrieved 29 January 2021.
Staff, European Medicines Agency, 2004. EMEA Scientific Discussion of Glivec Archived 20 September 2018 at the Wayback Machine
"Patent US5521184 - Pyrimidine derivatives and processes for the preparation thereof". google.com. Archived from the original on 15 December 2020. Retrieved 11 November 2016.
"Espacenet - results view". worldwide.espacenet.com. Archived from the original on 17 November 2018. Retrieved 29 January 2021.
Indian Supreme Court Decision paragraphs 5-6 Archived 6 July 2013 at the Wayback Machine
"Novartis v UoI, para 8-9". Archived from the original on 6 July 2013. Retrieved 29 January 2021.
Shamnad Basheer for Spicy IP 11 March 2006 First Mailbox Opposition (Gleevec) Decided in India Archived 21 October 2013 at the Wayback Machine
Staff, LawyersCollective. 6 September 2011 Novartis case: background and update – Supreme Court of India to recommence hearing Archived 21 October 2013 at the Wayback Machine
R. Jai Krishna and Jeanne Whalen for The Wall Street Journal. 1 April 2013 Novartis Loses Glivec Patent Battle in India Archived 26 October 2014 at the Wayback Machine
"IPAB Order Dated 26-Jun-2009 in Novartis v. Union of India | Patent Application | Patent". Scribd. Archived from the original on 22 October 2013. Retrieved 29 January 2021.
"W.P. No.24759 of 2006". Archived from the original on 20 October 2013. Retrieved 29 January 2021.
"Supreme Court rejects bid by Novartis to patent Glivec". Archived from the original on 17 December 2013.
"Novartis v UoI, Para 191". Archived from the original on 6 July 2013. Retrieved 29 January 2021.
"Novartis v UoI, Para 24-25". Archived from the original on 6 July 2013. Retrieved 29 January 2021.
"How the Indian judgment will reverberate across the world". Archived from the original on 18 January 2014.
"Patented drugs must be priced smartly". Archived from the original on 20 October 2013.
"Patent with a purpose, Prof. Shamnad Basheer, Indian Express, 3 April 2013". Archived from the original on 26 May 2013. Retrieved 29 January 2021.
Kevin Grogan for PharmaTimes. 27 February 2012 Novartis explains stance over India patent law challenge Archived 16 December 2014 at the Wayback Machine
Erklärung von Bern. 8 May 2007 Short questions and answers about the court case initiated by Novartis in India Archived 21 October 2013 at the Wayback Machine
"Shift in Novartis Strategy, The Telegraph". Archived from the original on 11 May 2013. Retrieved 29 January 2021.
Voris, Bob Van (14 July 2010). "Novartis Reaches $152.5 Million Sex-Bias Settlement". Archived from the original on 18 May 2018. Retrieved 29 January 2021 – via www.washingtonpost.com.
"Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules CII". Warning Letters. US Food and Drug Administration. 25 September 2008. Archived from the original on 10 February 2012. Retrieved 2009-08-05.
Wilson, Duff (30 September 2010). "Novartis Settles Off-Label Marketing Case". The New York Times. Archived from the original on 16 November 2018. Retrieved 16 January 2012.
"Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, reaches settlement agreement with US Attorney's Office" (press release). Novartis. 30 September 2010. Media Releases. Archived from the original on 17 October 2013. Retrieved 16 January 2012.
"U.S. Sues Novartis Again, Accusing It of Kickbacks". The New York Times. 26 April 2013. Archived from the original on 5 October 2019. Retrieved 27 April 2013.
"United States Files Complaint Against Novartis Pharmaceuticals Corp. for Allegedly Paying Kickbacks to Doctors in Exchange for Prescribing Its Drugs". The United States Department of Justice. 26 April 2013. Archived from the original on 13 April 2014. Retrieved 26 April 2013.
Andrew Pollack for The New York Times. 28 April 2011 Cheaper Drug to Treat Eye Disease Is Effective Archived 16 September 2018 at the Wayback Machine
Jeffreys, Branwen (6 May 2012). "Using Avastin for eye condition wet AMD 'could save NHS £84m'". bbc.com. Archived from the original on 6 November 2013. Retrieved 6 May 2012.
Copley, Caroline; Hirschler, Ben (24 April 2012), Potter, Mark (ed.), Novartis challenges UK Avastin use in eye disease, Reuters, archived from the original on 22 May 2013, retrieved 2012-04-29
Ben Adams for Pharmafile. 26 July 2012 Lucentis price cut ends PCT-Novartis dispute Archived 19 October 2013 at the Wayback Machine
Ben Adams for Pharma Times. 3 October 2012. Novartis to drop legal case against NHS body Archived 19 October 2013 at the Wayback Machine
Kana Inagaki for The Wall Street Journal. 11 August 2013 Novartis Hit by Scandal Over Japanese Drug Studies: Probes Uncover Altered Research Data; Swiss Giant Stands by Heart Medicine Diovan Archived 13 October 2013 at the Wayback Machine
Kana Inagaki for The Wall Street Journal. 12 August 2013. Novartis Drug Studies in Japan–Tracing Back the Questions Archived 18 October 2013 at the Wayback Machine
"Japan Criminal Probe Could Spell More Trouble for Novartis". The Wall Street Journal. 10 January 2014. Archived from the original on 2 March 2014.
"Data manipulation by staff gets Novartis into legal mess in Japan". Japan Herald. Archived from the original on 29 August 2014. Retrieved 2 July 2014.
"Greek Officials Hit Back at Novartis Bribery Allegations | GreekReporter.com". greece.greekreporter.com. 6 February 2018. Archived from the original on 1 November 2020. Retrieved 7 February 2018.
"Greek officials ban Novartis manager from leaving the country amid widening bribery probe: report | FiercePharma". www.fiercepharma.com. Archived from the original on 9 November 2020. Retrieved 7 February 2018.
"Greek Govt Alleges Official Ties to Drug Bribery Scandal". The New York Times. Associated Press. 5 February 2018. ISSN 0362-4331. Archived from the original on 16 November 2018. Retrieved 7 February 2018.
"Ν. Ηλιόπουλος: Και με τη βούλα της Δικαιοσύνης υπαρκτό το σκάνδαλο Novartis". capital.gr. Archived from the original on 27 July 2022. Retrieved 27 July 2022.
(http://www.dw.com), Deutsche Welle. "Novartis under investigation for bribery in Greece | Europe| News and current affairs from around the continent | DW | 22.01.2017". DW.COM. Archived from the original on 12 November 2020. Retrieved 7 February 2018.
"SEC.gov | SEC Charges Novartis AG with FCPA Violations". www.sec.gov. Archived from the original on 18 January 2021. Retrieved 25 June 2020.
"Novartis Hellas S.A.C.I. and Alcon Pte Ltd Agree to Pay over $233 Million Combined to Resolve Criminal FCPA Cases". www.justice.gov. 25 June 2020. Archived from the original on 13 January 2021. Retrieved 25 June 2020.
"Novartis admits $1.2m in payments to Trump lawyer". Financial Times. Archived from the original on 9 November 2020. Retrieved 10 May 2018.
Emma Court (16 July 2018.) Novartis had 'longer and more detailed' relationship with Trump lawyer Michael Cohen, Senate report finds Archived 15 November 2020 at the Wayback Machine. MarketWatch. Retrieved 21 August 2018.
White House Access for Sale: Michael Cohen, Novartis and the bid to sell access to the Trump administration Archived 13 November 2020 at the Wayback Machine. Retrieved 21 August 2018.
"Leprosy". www.who.int. Archived from the original on 31 January 2021. Retrieved 19 January 2021.
"WHO | WHO and Novartis extend agreement to treat millions of leprosy patients with free medicines". WHO. Archived from the original on 19 October 2015. Retrieved 19 January 2021.
"WHO | New Memorandum of Understanding for MDT". WHO. Archived from the original on 11 October 2014. Retrieved 19 January 2021.

who.int

"Leprosy". www.who.int. Archived from the original on 31 January 2021. Retrieved 19 January 2021.
"WHO | WHO and Novartis extend agreement to treat millions of leprosy patients with free medicines". WHO. Archived from the original on 19 October 2015. Retrieved 19 January 2021.
"WHO | New Memorandum of Understanding for MDT". WHO. Archived from the original on 11 October 2014. Retrieved 19 January 2021.

wipo.int

"Madrid Yearly Review 2024" (PDF). p. 22. Archived (PDF) from the original on 25 June 2024. Retrieved 18 September 2024.

patentscope.wipo.int

"Crystal Modification of a N-Phenyl-2-Pyrimidineamine Derivative, Processes for Its Manufacture and Its Use". Archived from the original on 22 October 2013. Retrieved 29 January 2021.

worldcat.org

search.worldcat.org

Macilwain, Colin (1 November 1998). "Berkeley teams up with Novartis in $50m plant genomics deal". Nature. 396 (6706): 5. Bibcode:1998Natur.396....5M. doi:10.1038/23772. ISSN 1476-4687. PMID 9817194.
Dalton, Rex (1 May 1999). "Berkeley dispute festers over biotech deal". Nature. 399 (6731): 5. Bibcode:1999Natur.399....5D. doi:10.1038/19807. ISSN 1476-4687. PMID 10331373.
Dalton, Rex (1 November 2003). "Syngenta ends plant-research deal with Berkeley". Nature. 426 (6964): 216. Bibcode:2003Natur.426..216D. doi:10.1038/426216a. ISSN 1476-4687. PMID 14628007.
Morse, Andrew (11 November 2013). "Novartis Sells Unit for $1.68 Billion". Wall Street Journal. ISSN 0099-9660. Archived from the original on 5 August 2020. Retrieved 21 January 2020.
McNeil, Donald G. Jr. (28 June 2010). "The Drug Industry: GlaxoSmithKline, Merck and Novartis Again Rank Highest on Access to Poor". The New York Times. ISSN 0362-4331. Archived from the original on 10 September 2020. Retrieved 21 January 2020.
"Greek Govt Alleges Official Ties to Drug Bribery Scandal". The New York Times. Associated Press. 5 February 2018. ISSN 0362-4331. Archived from the original on 16 November 2018. Retrieved 7 February 2018.

worldpharmanews.com

"Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL®". www.worldpharmanews.com. Archived from the original on 13 November 2009. Retrieved 29 January 2021.

wsj.com

online.wsj.com

Maclucas, Neil (24 January 2011). "Novartis to Buy Genoptix for $470 Million". Health. The Wall Street Journal. Archived from the original on 10 January 2014.
"NICE Backs Novartis's Tasigna For CML, Rejects BMS's Sprycel", The Wall Street Journal, online.wsj.com, 12 January 2012, archived from the original on 17 May 2013, retrieved 2012-01-15
R. Jai Krishna and Jeanne Whalen for The Wall Street Journal. 1 April 2013 Novartis Loses Glivec Patent Battle in India Archived 26 October 2014 at the Wayback Machine
Kana Inagaki for The Wall Street Journal. 11 August 2013 Novartis Hit by Scandal Over Japanese Drug Studies: Probes Uncover Altered Research Data; Swiss Giant Stands by Heart Medicine Diovan Archived 13 October 2013 at the Wayback Machine
"Japan Criminal Probe Could Spell More Trouble for Novartis". The Wall Street Journal. 10 January 2014. Archived from the original on 2 March 2014.

wsj.com

Roland, Denise (17 May 2016). "Novartis Pharmaceuticals Head to Depart Amid Restructuring". Wall Street Journal. Archived from the original on 5 August 2020. Retrieved 9 January 2020.
Morse, Andrew (11 November 2013). "Novartis Sells Unit for $1.68 Billion". Wall Street Journal. ISSN 0099-9660. Archived from the original on 5 August 2020. Retrieved 21 January 2020.

blogs.wsj.com

Kana Inagaki for The Wall Street Journal. 12 August 2013. Novartis Drug Studies in Japan–Tracing Back the Questions Archived 18 October 2013 at the Wayback Machine

yahoo.com

finance.yahoo.com

"Novartis to buy Mariana Oncology in radiopharmaceutical expansion". Yahoo Finance. 2 May 2024. Archived from the original on 3 May 2024. Retrieved 3 May 2024.
"Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV". finance.yahoo.com. 28 March 2018. Archived from the original on 5 August 2020. Retrieved 11 March 2019.

yahoo.com

"German regulators approve Novartis deal to buy drugmaker Morphosys". Yahoo News. 12 March 2024. Archived from the original on 12 March 2024. Retrieved 10 April 2024.